Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. is a Cayman Islands special purpose acquisition company formed to complete a merger or similar business combination. It raised capital through an IPO and private placement and is currently searching for a target, with a stated focus on the pharmaceutical industry.

0.03

0.03

— Drugs Made In America Acquisition Corp.
%
SPAC capital vehicle100% Publicly listed blank check structure used to raise cash for a future acquisition.

The company does not sell products or services to operating customers; its capital providers are public shareholders,...

  • Public IPO investorsprimary

    Buy units for trust-account exposure, redemption rights, and upside from a future deal

  • Sponsorprimary

    Provides private placement capital and initial support to fund the SPAC structure

  • Underwriterssecondary

    Distribute the IPO units and receive underwriting fees tied to the offering

  • Acquisition targetsprimary

    Pharmaceutical or other businesses that may be acquired in the initial business combination

The company is incorporated in the Cayman Islands but is managed from the United States and listed through a U.S...

  • •Cayman Islands incorporation
  • •United States capital markets listing and investor base
  • •Trust assets invested in U.S. Treasury obligations
  • •Target search may span any geography
  • •No operating revenue or operating-country concentration yet

The company’s near-term strategy is to identify and complete an initial business combination before the mandatory...

01
Identify a suitable pharmaceutical targetshort-term

The company has stated a sector focus, which should improve sourcing and diligence quality.

02
Complete the initial business combinationshort-term

The SPAC has no operating business until a transaction closes, so execution is existential.

03
Manage dilution and transaction economicsmedium-term

Redemptions, deferred underwriting fees, and sponsor economics affect the value of the deal.

The company faces the core SPAC risk that it may fail to identify and close a suitable business combination before...

critical

Failure to complete an initial business combination

The company has no operating business and must close a transaction within the combination period or liquidate.

Scope
All equity value depends on execution of the deal.
Materiality
high
critical

Going concern / liquidation deadline

Mandatory liquidation provisions create substantial doubt if a transaction is not completed in time.

Scope
Corporate survival as a going concern.
Materiality
high
high

Shareholder redemptions

Public investors can redeem shares, reducing cash available to fund the acquisition.

Scope
Transaction size and post-deal capitalization.
Materiality
high
high

Target sourcing and diligence risk

The company intends to focus on pharmaceuticals, which can narrow the opportunity set and increase diligence complexity.

Scope
Deal pipeline and closing probability.
Materiality
medium
Redeemable ordinary shares
Affects balance sheet classification and reported equity
Trust account interest income
Drives interim net income despite no operating revenue
Deferred underwriting commissions
Affects transaction economics and future cash available to the combined company
Offering costs and sponsor financing
Influences equity, cash flow, and reported transaction costs

Drugs Made In America Acquisition II Corp.

DMII · Blank Checks

FACT II Acquisition Corp.

FACT · Aircraft Parts & Auxiliary Equipment, NEC

Translational Development Acquisition Corp.

TDAC · Blank Checks

Fifth Era Acquisition Corp I

FERA · Blank Checks

Columbus Acquisition Corp/Cayman Islands

COLA · Blank Checks

Safeguard Acquisition Corp.

SAC · Blank Checks

: 28/04/2026